Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Recombinant Human Thrombopoietin Add to IST Combined with Hetrombopag As First-Line Treatment for Naïve Severe Aplastic Anemia: Early Outcomes of a Prospective Study

Huihui Fan, Wenrui Yang, Xin Zhao, Li Zhang, Liping Jing, Fengkui Zhang

Blood (2024) 144 (Supplement 1): 4086.

https://doi.org/10.1182/blood-2024-207840

Published: 2024

Journal Articles

Γδ and Αβ T-Cell Large Granular Lymphocytic Leukemia Have Similar Characteristics and Outcomes

Blood (2024) 144 (Supplement 1): 1678.

https://doi.org/10.1182/blood-2024-202457

Published: 2024

Journal Articles

Efficacy and Safety of HRS-5965 Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Have Not Received Complement Inhibitors: A Proof-of-Concept, Multicenter, Randomized, Open-Label Study

Fengkui Zhang, Bing Han, Li Zhang, Xin Zhao

Blood (2024) 144 (Supplement 1): 2688.

https://doi.org/10.1182/blood-2024-201147

Published: 2024

Journal Articles

A Phase 2 Dose-Finding Trial of MY008211A in Complement Inhibitor-Naive Patients with Paroxysmal Nocturnal Hemoglobinuria and Signs of Active Hemolysis

Fengkui Zhang, Li Zhang, Miao Chen, Hongyan Tong, Xiaoni Li, Wei Wang, Li Liu, Geoffrey Ross

Blood (2024) 144 (Supplement 1): 2701.

https://doi.org/10.1182/blood-2024-210973

Published: 2024

Journal Articles

KP104, a Bifunctional C5 Mab-Factor H Fusion Protein, Demonstrates Sustained Long-Term Efficacy and Safety in Complement Inhibitor-Naïve PNH Patients: Updated Results from a Phase 2 Study at 36/38 Weeks of Obd Treatment

Fengkui Zhang, Li Zhang, Chen Yang, Changhe Yue, Jay Ma, Chaomei He, Ping Tsui, Qing Yu Christina Weng, Helen Fu, Hui Yan, Wenru Song, Bing Han

Blood (2024) 144 (Supplement 1): 2699.

https://doi.org/10.1182/blood-2024-210086

Published: 2024

Journal Articles

Hetrombopag, an Emerging Iron-Chelating Agent, Alleviates Systemic Iron Overload

Zhao Yufei, Xin Zhao, Wenrui Yang, Fengkui Zhang

Blood (2024) 144 (Supplement 1): 3848.

https://doi.org/10.1182/blood-2024-201638

Published: 2024

Journal Articles

Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression

Blood (2024) 144 (Supplement 1): 4439.

https://doi.org/10.1182/blood-2024-201476

Published: 2024

Journal Articles

Thrombopoietin Receptor Agonist Added to Standard Immunosuppressive Therapy for Hepatitis-Associated Aplastic Anemia

Min Wang, Meili Ge, Liwei Fang, Liping Jing, Yingchang Mi, Fengkui Zhang, Yizhou Zheng, Jun Shi

Blood (2024) 144 (Supplement 1): 5687.

https://doi.org/10.1182/blood-2024-207385

Published: 2024

Journal Articles

Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial

Blood (2024) 144 (Supplement 1): 304.

https://doi.org/10.1182/blood-2024-206377

Published: 2024

Journal Articles

Ianalumab, a Novel Anti-B-Cell Activating Factor (BAFF) Receptor (BAFF-R) Monoclonal Antibody (mAb) in Development for Immune Thrombocytopenia (ITP) and Warm Autoimmune Hemolytic Anemia (wAIHA), Has Demonstrated a Favorable Safety Profile in Sjögren's Syndrome (SjS), Systemic Lupus Erythematosus (SLE) and Chronic Lymphocytic Leukemia (CLL)

Adam Cuker, Hanny Al-Samkari, Wilma Barcellini, Nichola Cooper, Waleed Ghanima, Marc Michel, Raymond SM Wong, Francesco Zaja, Fengkui Zhang, Patrick Urban, Roberto Abi Rached, David J Kuter

Blood (2023) 142 (Supplement 1): 5427.

https://doi.org/10.1182/blood-2023-180055

Published: 2023

Journal Articles

Efficacy and Safety of Recombinant Thrombopoietin Combined with Immunosuppressive Therapy for Primary Treatment of Severe Aplastic Anemia: A Single-Center, Open-Label, Randomized, Clinical Trial

Wenrui Yang, Xin Zhao, Guangxin Peng, Huihui Fan, Kang Zhou, Lei Ye, Jianping Li, Yuan Li, Liping Jing, Li Zhang, Fengkui Zhang

Blood (2023) 142 (Supplement 1): 1348.

https://doi.org/10.1182/blood-2023-179958

Published: 2023

Journal Articles

A Preliminary Report of Clinical Study on Immunosuppressive Therapy Combined with Avatrombopag As the First-Line Treatment for Severe Aplastic Anaemia in Elderly Patients

Lei Ye, Xin Zhao, Liping Jing, Guangxin Peng, Fengkui Zhang, Li Zhang

Blood (2023) 142 (Supplement 1): 1351.

https://doi.org/10.1182/blood-2023-180953

Published: 2023

Journal Articles

The Role of Red Blood Cell Lifespan Testing in the Evaluation of Patients with Paroxysmal Nocturnal Hemoglobinuria

Lei Ye, Xin Zhao, Liping Jing, Fengkui Zhang, Li Zhang

Blood (2023) 142 (Supplement 1): 5652.

https://doi.org/10.1182/blood-2023-181404

Published: 2023

Journal Articles

Myopathy with Lactic Acidosis and Sideroblastic Anemia Caused By a Novel PUS1 mutation

Youzhen Xiong, Wenrui Yang, Huihui Fan, Li Zhang, Xin Zhao, Liping Jing, Fengkui Zhang

Blood (2023) 142 (Supplement 1): 5242.

https://doi.org/10.1182/blood-2023-182770

Published: 2023

Journal Articles

Avatrombopag in Combination with Immunosuppressive Therapy for Hepatitis-Associated Aplastic Anemia

Wenrui Yang, Xin Zhao, Youzhen Xiong, Huihui Fan, Jianping Li, Lei Ye, Li Zhang, Liping Jing, Fengkui Zhang

Blood (2023) 142 (Supplement 1): 4091.

https://doi.org/10.1182/blood-2023-179722

Published: 2023

Journal Articles

IST Combined with Full-Dose Rhtpo in the Treatment of Severe Aplastic Anemia -a Prospective Single-Center Clinical Study

Huihui Fan, Jing Hu, Wenrui Yang, Xin Zhao, Li Zhang, Kang Zhou, Youzhen Xiong, Liping Jing, Fengkui Zhang

Blood (2023) 142 (Supplement 1): 4086.

https://doi.org/10.1182/blood-2023-182717

Published: 2023

Journal Articles

Early Efficacy of IST in Combination with Hetrombopag and Rhtpo As First-Line Treatment for Naïve Severe Aplastic Anemia

Huihui Fan, Wenrui Yang, Xin Zhao, Li Zhang, Youzhen Xiong, Liping Jing, Fengkui Zhang

Blood (2023) 142 (Supplement 1): 5634.

https://doi.org/10.1182/blood-2023-182794

Published: 2023

Journal Articles

Comparison of Hematopoietic Stem Cell Transplantation and Repeated Immunosuppressive Therapy As Second-Line Treatment for Relapsed/Refractory Severe Aplastic Anemia

Lining Zhang, Jianping Li, Weiru Liang, Jialin Wei, Yi He, Erlie Jiang, Fengkui Zhang, Mingzhe Han, Sizhou Feng

Blood (2023) 142 (Supplement 1): 7095.

https://doi.org/10.1182/blood-2023-179202

Published: 2023

Journal Articles

Avatrombopag Is Effective in First-Line Treatment of Severe Aplastic Anemia: Early Outcomes of a Prospective Study

Xin Zhao, Jianping Li, Huihui Fan, Liping Jing, Li Zhang, Kang Zhou, Wenrui Yang, Yuan Li, Yang Yang, Lei Ye, Guangxin Peng, Youzhen Xiong, Jun Shi, Fengkui Zhang

Blood (2023) 142 (Supplement 1): 4087.

https://doi.org/10.1182/blood-2023-190948

Published: 2023

Journal Articles

Comparison between Hetrombopag and Eltrombopag Combined with IST As First-Line Treatment for Severe Aplastic Anemia

Wenrui Yang, Baohang Zhang, Xiangrong Hu, Li Zhang, Liping Jing, Xin Zhao, Fengkui Zhang

Blood (2023) 142 (Supplement 1): 2721.

https://doi.org/10.1182/blood-2023-186123

Published: 2023

NARROW

Recombinant Human Thrombopoietin Add to IST Combined with Hetrombopag As First-Line Treatment for Naïve Severe Aplastic Anemia: Early Outcomes of a Prospective Study

Γδ and Αβ T-Cell Large Granular Lymphocytic Leukemia Have Similar Characteristics and Outcomes

Efficacy and Safety of HRS-5965 Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Have Not Received Complement Inhibitors: A Proof-of-Concept, Multicenter, Randomized, Open-Label Study

A Phase 2 Dose-Finding Trial of MY008211A in Complement Inhibitor-Naive Patients with Paroxysmal Nocturnal Hemoglobinuria and Signs of Active Hemolysis

KP104, a Bifunctional C5 Mab-Factor H Fusion Protein, Demonstrates Sustained Long-Term Efficacy and Safety in Complement Inhibitor-Naïve PNH Patients: Updated Results from a Phase 2 Study at 36/38 Weeks of Obd Treatment

Hetrombopag, an Emerging Iron-Chelating Agent, Alleviates Systemic Iron Overload

Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression

Thrombopoietin Receptor Agonist Added to Standard Immunosuppressive Therapy for Hepatitis-Associated Aplastic Anemia

Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial

Efficacy and Safety of Recombinant Thrombopoietin Combined with Immunosuppressive Therapy for Primary Treatment of Severe Aplastic Anemia: A Single-Center, Open-Label, Randomized, Clinical Trial

A Preliminary Report of Clinical Study on Immunosuppressive Therapy Combined with Avatrombopag As the First-Line Treatment for Severe Aplastic Anaemia in Elderly Patients

The Role of Red Blood Cell Lifespan Testing in the Evaluation of Patients with Paroxysmal Nocturnal Hemoglobinuria

Myopathy with Lactic Acidosis and Sideroblastic Anemia Caused By a Novel PUS1 mutation

Avatrombopag in Combination with Immunosuppressive Therapy for Hepatitis-Associated Aplastic Anemia

IST Combined with Full-Dose Rhtpo in the Treatment of Severe Aplastic Anemia -a Prospective Single-Center Clinical Study

Early Efficacy of IST in Combination with Hetrombopag and Rhtpo As First-Line Treatment for Naïve Severe Aplastic Anemia

Comparison of Hematopoietic Stem Cell Transplantation and Repeated Immunosuppressive Therapy As Second-Line Treatment for Relapsed/Refractory Severe Aplastic Anemia

Avatrombopag Is Effective in First-Line Treatment of Severe Aplastic Anemia: Early Outcomes of a Prospective Study

Comparison between Hetrombopag and Eltrombopag Combined with IST As First-Line Treatment for Severe Aplastic Anemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only